Targeted siRNA-lactobionic lipid nanoparticles with novel ionizable lipid inhibit antithrombin III expression in hepatocytes

Targeted reduction of hepatic antithrombin (AT) via siRNA offers a promising strategy to enhance thrombin (TMB) generation in bleeding disorders, though efficient hepatocyte delivery remains challenging. This study developed and evaluated a targeted lipid nanoparticle (LNP) formulation incorporating a novel morpholine-based ionizable lipid (MIL) and a lactobionic-octadecylamine conjugate (LBN) for hepatocyte-specific delivery of AT-siRNA (siAT). Following synthesis of MIL and LBN, siAT-loaded LNP (siAT LNP LBN) were prepared using microfluidics and characterized for size, morphology, zeta potential, polydispersity index, and encapsulation efficiency (EE). Functional assays on HepG2 cells assessed cellular uptake, protein knockdown, and AT activity. The optimized formulation exhibited uniform particles (124 nm, PDI 0.125, zeta potential - 8.9 mV) and high EE (90%). Cytotoxicity assays confirmed safety up to 65 pmol siRNA. LBN-decorated LNP significantly enhanced hepatocyte uptake compared to non-targeted LNP and naked siRNA. Optimal AT mRNA suppression occurred at ~ 65 pmol siRNA and 16 h, with protein knockdown confirmed at 48 h. Functionally, siAT LNP LBN reduced AT activity to 48.1 ± 5.5%, substantially outperforming non-targeted LNP (64.1%) and naked siRNA (86.6%). The developed siAT-LNP-LBN platform demonstrated efficient hepatocyte uptake, robust AT knockdown, and low cytotoxicity in vitro, providing preliminary evidence for its potential as a hepatocyte-targeted siRNA delivery platform. Further in vivo studies are warranted to evaluate its biodistribution, liver-targeting efficiency, pharmacodynamic effects, therapeutic efficacy, and biosafety.

Authors

Institutions

Publication Details

Journal
Discover Nano
Published
2026-11-16
DOI
https://doi.org/10.1186/s11671-026-05012-8
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeted siRNA-lactobionic lipid nanoparticles with novel ionizable lipid inhibit antithrombin III expression in hepatocytes

Seyed Milad Safar Sajadi, Ali Rajabi Zangi, Hamid Reza Heidari, Hamed Hamishehkar et al.
1 links
Discover Nano
RNA Interference and Gene Delivery
article

Targeted siRNA-lactobionic lipid nanoparticles with novel ionizable lipid inhibit antithrombin III expression in hepatocytes

Seyed Milad Safar Sajadi, Ali Rajabi Zangi, Hamid Reza Heidari, Hamed Hamishehkar, Yousef Javadzadeh, Seyed Hossein Kiaie
article en

Abstract

Targeted reduction of hepatic antithrombin (AT) via siRNA offers a promising strategy to enhance thrombin (TMB) generation in bleeding disorders, though efficient hepatocyte delivery remains challenging. This study developed and evaluated a targeted lipid nanoparticle (LNP) formulation incorporating a novel morpholine-based ionizable lipid (MIL) and a lactobionic-octadecylamine conjugate (LBN) for hepatocyte-specific delivery of AT-siRNA (siAT). Following synthesis of MIL and LBN, siAT-loaded LNP (siAT LNP LBN) were prepared using microfluidics and characterized for size, morphology, zeta potential, polydispersity index, and encapsulation efficiency (EE). Functional assays on HepG2 cells assessed cellular uptake, protein knockdown, and AT activity. The optimized formulation exhibited uniform particles (124 nm, PDI 0.125, zeta potential - 8.9 mV) and high EE (90%). Cytotoxicity assays confirmed safety up to 65 pmol siRNA. LBN-decorated LNP significantly enhanced hepatocyte uptake compared to non-targeted LNP and naked siRNA. Optimal AT mRNA suppression occurred at ~ 65 pmol siRNA and 16 h, with protein knockdown confirmed at 48 h. Functionally, siAT LNP LBN reduced AT activity to 48.1 ± 5.5%, substantially outperforming non-targeted LNP (64.1%) and naked siRNA (86.6%). The developed siAT-LNP-LBN platform demonstrated efficient hepatocyte uptake, robust AT knockdown, and low cytotoxicity in vitro, providing preliminary evidence for its potential as a hepatocyte-targeted siRNA delivery platform. Further in vivo studies are warranted to evaluate its biodistribution, liver-targeting efficiency, pharmacodynamic effects, therapeutic efficacy, and biosafety.

Discover NanoVol. 21(1)
Khazar University (AZ), Tabriz University of Medical Sciences (IR), University of Tehran (IR), Biotechnology Research Center (IR)
Tabriz University of Medical Sciences, University of Tabriz
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon